今天让我们一起来通过文献来了解犬特应性皮炎与IL-31水平相关性,让我们开启愉快的学习之旅哦~
Lokivetmab(犬抗IL-31单克隆抗体)治疗特应性皮炎犬瘙痒的临床疗效与血清白细胞介素31水平的相关性
Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab
摘要:
关键词:特应性皮炎,IL-31,Lokivetmab(犬抗IL-31单克隆抗体),单克隆抗体,瘙痒症
介绍:
试验方法:
表1。来自一家兽医教学医院皮肤科服务的10只特应性皮炎犬的人口统计学数据。
品种 | |||||
已绝育 | |||||
巴哥 | |||||
巴哥 | |||||
瘙痒症视觉模拟量表 (pVAS)
为了评估瘙痒,主人被要求根据他们对瘙痒的感知,在适应的pVAS上标记动物当时的位置。随后,将另一个刻度从零到十厘米叠加在所有者标记的刻度上,并记录数值。pVAS评分以厘米为单位进行评估,分类如下:正常犬:0-1.9 cm;轻度瘙痒:2-4 cm;中度瘙痒:>4-6 cm;严重瘙痒:>6-8 cm;非常严重瘙痒:>8-10 cm。犬类特应性皮炎的严重程度
及严重程度指数 (CADESI)
CADESI评分也被用于对狗的疾病严重程度进行分类,并通常用于量化犬类AD的临床效果。CADESI-04基于红斑的评估,红斑是急性炎症的标志物,是慢性疾病的标志物和脱发的结合,是身体不同部位瘙痒的标志物。
对20个评估区域的所有特征建立了4分严重程度量表,包括无(0分)、轻度(1分)、中度(2分)和严重(3分)。根据这些评分将疾病严重程度分为:轻度:评分在10-35之间;中度:>35-60;严重:>60-180。三名训练有素的评分者进行了CADESI-04测试。记录个体得分值并求和,最终值作为三个得分的平均值。
血液样本
为了评估它们的总体健康状况,所有的狗在研究 前都进行了颈静脉或头静脉穿刺,收集5 mL的血液进行血细胞计数(2 mL)和生化(3 mL)。在M0、M1和M2时,收集4 mL的血液 ,以获得2 mL的血清,用于后续测量IL-31。
犬IL-31的测量
为了特异性检测和测量犬血清IL-31,使用了一种市售试剂盒 (犬白细胞介素-31 ELISA kit,灵敏度为1 pg/mL。根据制造商的建议,在所有时间点进行测量。
在治疗前 (M0) ,平均pVAS为7.4(±1.4),M1为4.7(±1.8),M2为5.0(±1.2)。研究中的大多 数狗 (80%) 在治疗前有非常严重或严重的瘙痒(M0)。第一次注射单抗 (M1)后,无犬类出现非常严重瘙痒,出现严重瘙痒的犬类数量减少到30%。此外,70%的狗出现中度或轻度瘙痒(分别为20%和50%)。经过两次注射 (M2)后,没有一只狗出现非常严重的瘙痒,只有10%的狗出现严重瘙痒,而60%和30%的狗出现中度和轻度瘙痒。
图1:治疗各时刻(M0、M1、M2)pVAS评分散点图。每个组上面的字母代表了多重比较。
在M0和M1之间、M0和M2之间的pVAS值有统计学差异(ρ<0.001) ,但在处理时间点M1和M2之间无统计学差异(图1),显示瘙痒症最显著的减轻发生在第一次注射后4周。
当观察到pVAS评分中降低大于2cm时,犬抗IL-31单克隆抗体对瘙痒的反应被认为是令人满意的。降低大于50%被定义为显著反应。在第一次注射后,只有20%的狗(2/10)检测到这种情况。没有一只狗的瘙痒值达到了被认为是正常的(0-1.9厘米),即主人不需要寻求兽医介入的水平。然而,平均pVAS评分在M0和M1之间下降到2.7 cm,在M0和M2之间下降到2.4 cm。
根据CADESI-04基线评分,研究中的狗都有轻微的疾病严重程度。三个时间点间的CADESI-04评分 (ρ=0.515) ,差异无统计学意义(图2)。
图2:在治疗的各时刻(M0、M1和M2),CADESI-04评分的散点图。每个组上面的字母代表了多重比较。
在所有AD犬中均检测到IL-31,在犬抗IL-31单克隆抗体治疗前的平均值为255.91 pg/mL(±108.3) 。在第一次和第二次注射犬抗IL-31单克隆抗体后,10只狗中有8只狗的血清中该细胞因子水平降低。在M0、M1和M2时刻,4 只犬的血清IL-31水平逐渐下降。其余4个只在M0和M1 之间出现减少,在M2中再次增加。只有一只狗(7)的 M1和M2比M0增加。M0与M2之间的血清IL-31水平差异有统计学意义 (ρ=0.031) 。然而,在M0和M1和M1 和M2之间没有观察到这种差异(图3)。此外,虽然在统计学上差异较弱,但pVAS评分与血清IL-31水平之间存在显著正相关(ρ=0.047,R=0.37) 。(图4)
图4:在所有治疗时间(M0、M1、M2)时,血清IL-31水平与pVAS评分之间的相关性散点图。
结果进一步证明了IL-31直接参与了AD犬的瘙痒症发病机制。
此外,阻断IL-31具有显著的止痒作用,但对皮肤病变的严重程度和发展无影响。
犬抗IL-31单克隆抗体(Cytopoint®,Zoetis)犬抗IL-31单克隆抗体
参考文献:
Favrot C, Steffan J, Seewald W, Picco F (2010) A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol 21: 23-30.
Gonzales AJ, Humphrey WR, Messamore JE, Fleck TJ, Fici GJ, Shelly JA, Teel JF, Bammert GF, Dunham SA, Fuller TE, McCall RB (2013) Interleukin31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 24: 48-53.
Halliwell R (2006) Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol 114: 207-208.
Hill PB, Lau P, Rybníček J (2007) Development of an owner-assessed scale to measure the severity of pruritus in dogs. Vet Dermatol 5: 301-308.
Jackson H, Forsythe P. New therapies for canine atopic dermatitis (2020). In Pract 42: 82- 90.
Marsella R, Ahrens K, Sanford R (2018) Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using Beagle dogs. Vet Dermatol 29: 69-e28.
Marsella R, De Benedetto A (2017) Atopic dermatitis in animals and people: An update and comparative review. Vet Sci 4: 1-19.
Marsella R, Samuelson D (2009) Unravelling the skin barrier: A new paradigm for atopic dermatitis and house dust mites. Vet Dermatol 20: 533-540.
Michels GM, Ramsey DS, Walsh KF, Martinon OM, Mahabir SP, Hoevers JD, Walters RR, Dunham SA (2016) A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 27: 478-e129.
Miller WH, Griffin CE, Campbell KL (2013) Small animal dermatology. St. Louis, Missouri: Elsevier.
Moyaert H, Brussel LV, Borowski S, Escalada M, Mahabir SP, Walters RR, Stegemann MR (2017) A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 28: 593- e145.
Olivry T, Banovic F (2019) Treatment of canine atopic dermatitis: time to revise our strategy? Vet Dermatol 30: 87-90.
Olivry T, DeBoer DJ, Griffin CE, Halliwell RE, Hill PB, Hillier A, Marsella R, Sousa CA (2001) The ACVD task force on canine atopic dermatitis. Vet Immunol Immunopathol 81: 143-146.
Olivry T, Saridomichelakis MN, Nuttall T, Bensignor E, Griffin CE, Hill PB (2014) Validation of the canine atopic dermatitis extent and severity index (CADESI-04, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. Vet Dermatol 25: 77-86.
Ribeiro JFA (2019) Evaluation of dermatological inflammatory response in atopic dogs using oclacitinib maleate. Dissertation (Masters) - Paulista State University Júlio de Mesquita Filho, Faculty of Veterinary Medicine and Animal Science, Botucatu.
Rybníček J, Lau-Gillard PJ, Harvey R, Hill PB (2009) Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 20: 115-122.
Santoro D (2019) Therapies in Canine Atopic Dermatitis: An update. Vet Clin North Am Small Anim Pract 49: 9-26.
Saridomichelakis MN, Olivry T (2016). An update on the treatment of canine atopic dermatitis. Vet J 207:29-37.
Souza CP, Rosychuk RAW, Contreras ET, Schissler JR, Simpson AC (2018) A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol 29: 489-e164.
Szczepanik MP, Popiel J, Cekiera A, Pomorska-Handwerker D, Karaś-Tęcza J, Ściskalska M, Oczkowska K, Taube M, Olender V, Parys P (2020) Evaluation of the clinical efficiency of lokivetmab in client privately owned atopic dogs – multicenter study. Pol J Vet Sci 23: 191-195.
Szczepanik MP, Wilkołek P, Gołyński M, Sitkowski W, Taszkun I, Toczek W (2019) The influence of addition to lokivetmab treatment on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis. Vet Dermatol 30: 330-e93.
Tamamoto-Mochizuki C, Paps JS, Olivry T (2019) Proactive maintenance therapy of canine atopic dermatitis with the anti-IL-31 lokivetmab. Can a monoclonal antibody blocking a single cytokine prevent allergy flares? Vet Dermatol 30: 98-e26.
内容来源:《Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab》
J.R.Calesso1,V.S.Marques1,O.V.deCarvalho2,A.P.Costa-Val1*
DOI:10.24425/pjvs.2023.145027